Form 4: Applied Therapeutics Director Stacy Kanter Receives 200,000 Stock Options

Applied Therapeutics, Inc. director Stacy J. Kanter was granted 200,000 stock options with an exercise price of $0.395, vesting over 36 months.

Summary

• Stacy J. Kanter, a Director of Applied Therapeutics, Inc. (APLT), was granted 200,000 stock options.
• The stock options have an exercise price of $0.395 per share.
• The grant date for these options was June 9, 2025.
• The options will vest in 36 equal monthly installments from the grant date, contingent on Ms. Kanter's continuous service.
• The expiration date for these stock options is June 9, 2035.
• Following this transaction, Stacy J. Kanter beneficially owns 200,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it represents a compensation expense, it aligns the director's interests with shareholders and is a standard practice for incentivizing long-term commitment.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule over 36 months encourages the director's continued service and commitment to the company.

Negatives

• The issuance of new stock options, if exercised, could lead to a slight dilution of existing shareholder equity, although this is a standard component of executive and director compensation.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across industries, particularly in the biotechnology and pharmaceutical sectors like Applied Therapeutics, to attract and retain talent and align interests with long-term company success.

Corporate Governance

Related Party Transactions

• The grant of 200,000 stock options to Stacy J. Kanter, a director of Applied Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (Stacy J. Kanter): Receives equity-based compensation, incentivizing continued service and performance.

Next Steps

• The stock options will continue to vest in 36 equal monthly installments from the grant date, subject to the director's continuous service.

Key Dates

Keywords

Applied Therapeutics, APLT, Stock Option, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4, Beneficial Ownership